Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Rank in Stocks #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Share Price
$28.53
Market Cap
$1.96B
Change (1 day)
-1.65%
Change (1 year)
109.32%
Country
IE
Trade GH Research PLC (GHRS)

Category

Stock split history for GH Research PLC (GHRS)
GH Research PLC stock (symbol: GHRS) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 27, 2026.
One GHRS share bought prior to Aug 27, 2026 would equal to 0 GHRS shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH